GLAUKOS CORP. news, videos and press releases
For more news please use our advanced search feature.
GLAUKOS CORP. - More news...
GLAUKOS CORP. - More news...
- Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
- RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
- Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
- Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
- Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
- Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
- Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
- Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos
- Glaukos Announces Participation in Wells Fargo Healthcare Conference
- Glaukos Announces Second Quarter 2023 Financial Results
- Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
- Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
- Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
- Glaukos Announces Participation in the William Blair Growth Stock Conference
- Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
- Glaukos Announces First Quarter 2023 Financial Results
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
- Glaukos Announces the Release of its 2022 Sustainability Report
- Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
- Glaukos Submits New Drug Application to U.S. FDA for iDose TR
- Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
- Glaukos Announces Participation in the Citi Healthcare Conference
- Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
- Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
- Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
- Glaukos Announces Participation in the Stephens Annual Investment Conference
- Glaukos Corporation Announces Third Quarter 2022 Financial Results
- Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
